Breaking News
February 23, 2019 - Surprise rheumatoid arthritis discovery points to new treatment for joint inflammation
February 23, 2019 - A just-right fix for a tiny heart
February 23, 2019 - Owlstone Medical and Shanghai Renji Hospital collaborate to initiate breath biopsy lung cancer trial
February 23, 2019 - AMSBIO’s comprehensive portfolio of knock-out cell lines and lysates
February 23, 2019 - New app reliably determines physicians’ skills in forming accurate, efficient diagnoses
February 23, 2019 - Peripheral nerve injury can trigger the onset and spread of ALS, shows study
February 23, 2019 - Researchers uncover mechanisms that prevent tooth replacement in mice
February 23, 2019 - Once-a-day capsule offers new way to reduce symptoms of chronic breathlessness
February 23, 2019 - FDA Adds Boxed Warning for Increased Risk of Death with Gout Medicine Uloric (febuxostat)
February 23, 2019 - Phone-based intervention aids rheumatoid arthritis care
February 23, 2019 - Opioid epidemic makes eastern inroads and targets African-Americans
February 23, 2019 - New identified biomarker predicts patients who might benefit from HER2-targeted agents
February 23, 2019 - Study offers new insights into mechanisms of changes in erythrocytes under stress
February 23, 2019 - Antipsychotic polypharmacy may be beneficial for schizophrenia patients
February 23, 2019 - Researchers investigate how marijuana and tobacco co-use affects quit attempts by smokers
February 23, 2019 - Patients with diabetes mellitus have high risk of stable ischemic heart disease
February 23, 2019 - Transparency on healthcare prices played key role in Arizona health system’s turnaround
February 23, 2019 - A comprehensive, multinational review of peppers around the world
February 23, 2019 - Study finds modest decrease in burnout among physicians
February 23, 2019 - A simple change can drastically reduce unnecessary tests for urinary tract infections
February 23, 2019 - Deep Learning-Enhanced Device Detects Diabetic Retinopathy
February 23, 2019 - Researchers discover new binding partner for amyloid precursor protein
February 23, 2019 - Modest decrease seen in burnout among physicians, researchers say | News Center
February 23, 2019 - Transplanting bone marrow of young mice into old mice prevents cognitive decline
February 23, 2019 - Mogrify to accelerate novel IP and cell therapies using $3.7m USD funding
February 23, 2019 - Johns Hopkins study describes cells that may help speed bone repair
February 23, 2019 - Scientists demonstrate influence of food odors on proteostasis
February 23, 2019 - Researchers unlock the secret behind reproduction of fish called ‘Mary’
February 23, 2019 - Acupuncture Could Help Ease Menopausal Symptoms
February 23, 2019 - Researchers use AI to detect early signs of Alzheimer’s
February 23, 2019 - On recovery, vulnerability and ritual: An exhibit in white | News Center
February 23, 2019 - Memory Stored in Unexpected Region of the Brain
February 23, 2019 - Several health experts worldwide gather at EUDONORGAN event
February 23, 2019 - Discovery of potent compound in native California shrub may lead to treatment for Alzheimer’s
February 22, 2019 - Researchers create new map of the brain’s own immune system
February 22, 2019 - ICHE’s reviews on surgical infections, unnecessary urine tests, and nurses’ role in antibiotic stewardship
February 22, 2019 - UK Research and Innovation invests £200 million to create new generation of AI leaders
February 22, 2019 - Takeda collaboration to boost fight against Alzheimer’s and other neurodegenerative diseases
February 22, 2019 - Heavy drinking may change DNA, leading to increased craving for alcohol
February 22, 2019 - U.S. opioid deaths jump fourfold in 20 years; epidemic shifts to Eastern states | News Center
February 22, 2019 - 5 Questions with William Turner on Diversity in Medicine
February 22, 2019 - HHS Finalizes Rule Seeking To Expel Planned Parenthood From Family Planning Program
February 22, 2019 - Researchers uncover biochemical pathway that may help identify drugs to treat Alzheimer’s
February 22, 2019 - Biologist uses new grant to find ways to eliminate schistosomiasis
February 22, 2019 - Bag-mask ventilation to help patients breathe during intubation prevents complications
February 22, 2019 - AbbVie Announces New Drug Application Accepted for Priority Review by FDA for Upadacitinib for Treatment of Moderate to Severe Rheumatoid Arthritis
February 22, 2019 - Nature versus nurture and addiction
February 22, 2019 - New website connects researchers with data experts, resources | News Center
February 22, 2019 - Today’s Concerns About Drug Prices Echo The Past
February 22, 2019 - CT and Doppler equipment have low accuracy in detecting cerebral vasospasm and ischemia
February 22, 2019 - Study finds out similarity in function between healthy retina cell and tumor cell
February 22, 2019 - CWRU awarded NIH grant to identify effective treatments for intimate partner violence
February 22, 2019 - Oncotype DX Not Cost-Effective for Low-Risk Breast Cancer
February 22, 2019 - Scientists discover new type of immune cells that are essential for forming heart valves
February 22, 2019 - Talk About Déjà Vu: Senators Set To Re-Enact Drug Price Hearing Of 60 Years Ago
February 22, 2019 - Genetic defect linked to pediatric liver disease identified
February 22, 2019 - New cellular atlas could provide a deeper insight into blinding diseases
February 22, 2019 - Growing number of cancer survivors, fewer providers point to challenge in meeting care needs
February 22, 2019 - Innovative compound offers a new therapeutic approach to treat multiple sclerosis
February 22, 2019 - $1.5 million grant to develop opioid treatment program for jail detainees
February 22, 2019 - FDA’s new proposed rule would update regulatory requirements for sunscreen products in the U.S
February 22, 2019 - Most Hip, Knee Replacements Last Decades, Study Finds
February 22, 2019 - Wellness problems prevalent among ob-gyn residents
February 22, 2019 - In the Spotlight: “The world is your oyster in geriatrics”
February 22, 2019 - Successful testing of multi-organ “human-on-a-chip” could replace animals as test subjects
February 22, 2019 - Analysis of cervical precancer shows decline in two strains of HPV
February 22, 2019 - Sugary stent eases suturing of blood vessels
February 22, 2019 - From surgery to psychiatry: A medical student reevaluates his motivations
February 22, 2019 - Is New App From Feds Your Answer To Navigating Medicare Coverage? Yes And No
February 22, 2019 - New pacemakers powered by heartbeats could reduce need for surgery
February 22, 2019 - The United States records highest drug overdose death rates
February 22, 2019 - Heart attacks more likely to be fatal in women and rates are rising
February 22, 2019 - Morning walks could be better than drugs at lowering blood pressure
February 22, 2019 - Phase 1 data reinforce safety profile of new drug for treating Duchenne muscular dystrophy
February 22, 2019 - Vitamin D supplementation less effective in the presence of obesity, shows study
February 22, 2019 - Novostia raises CHF 6.5 million to advance its aortic, mitral heart valve to clinical trials
February 22, 2019 - CPRIT awards nearly $20 million to The University of Texas MD Anderson Cancer Center
February 22, 2019 - Sarepta Announces FDA Acceptance of Golodirsen (SRP-4053) New Drug Application for Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 53
February 22, 2019 - An institutional effort to reduce the amount of opioids prescribed following lumbar surgery
February 22, 2019 - Family-history-based models perform better than non-family-history based models
New clinical trial to evaluate virotherapy and immunotherapy combination for ovarian, colorectal cancers

New clinical trial to evaluate virotherapy and immunotherapy combination for ovarian, colorectal cancers

image_pdfDownload PDFimage_print

Ludwig Cancer Research and the Cancer Research Institute (CRI) announce the initiation of a clinical trial to evaluate the combination of ONCOS-102, an experimental anti-tumor virotherapy, with the checkpoint blockade antibody IMFINZI® (durvalumab) for advanced ovarian and colorectal cancers.

The Phase I/II trial, which has completed enrollment and the safety evaluation for the first patient cohort, could ultimately enroll as many as 78 adult patients in a multi-center program at leading academic centers including Memorial Sloan Kettering Cancer Center (MSK), the Roswell Park Cancer Institute, Sylvester Comprehensive Cancer Center at the University of Miami (UM/Sylvester) and the University of Virginia Health System (UVA). It is chaired by Ludwig and CRI investigator Dmitriy Zamarin of MSK. Kunle Odunsi of the Roswell Park Cancer Institute and Brian Slomovitz of UM/Sylvester are overseeing the trial at their respective institutions with locations to be added for the new cohorts. MedImmune, the global biologics research and development arm of AstraZeneca that developed durvalumab, and Targovax, the biopharmaceutical company that developed ONCOS-102, are also collaborators in the clinical trial.

“Patients diagnosed with advanced ovarian and colorectal cancers that have progressed on standard therapies have very few treatment options available to them,” said Vanessa Lucey, director of the CRI Venture Fund and Clinical Accelerator. “Under a unique partnership model, this study leverages the capabilities of two prominent nonprofit groups, accelerates innovation with top academic centers, and includes two different bio-pharmaceutical companies. This is the type of coordination and collaboration we need to accelerate progress for patients.”

“Although checkpoint blockade antibodies have been remarkably effective in treating a variety of cancers, many patients fail to respond to these immunotherapies,” said Jonathan Skipper, Ludwig’s executive vice president for technology development. “Eliciting therapeutic responses in such patients through combination therapies is a top priority of Ludwig’s clinical research program, and a major objective of CRI’s as well. We have good reason to believe that combining checkpoint blockade with oncolytic virotherapy is a highly promising strategy to that end. We very much look forward to seeing the results of this trial.”

ONCOS-102 is a serotype 5 adenovirus–a relative of the cold virus–that has been engineered to selectively infect and kill cancer cells. The virus has also been modified to express a gene for an immune factor known as granulocyte-macrophage colony stimulating factor (GM-CSF), which boosts critical elements of the immune response. ONCOS-102 has been shown in a previous trial to be safe and to induce anti-cancer immune responses.

Durvalumab, which is already approved for clinical use in other cancers, is a human monoclonal antibody directed against PD-L1. PD-L1 ordinarily protects healthy cells from destruction by a runaway immune response. Tumor cells, however, can co-opt PD-L1 to evade attack by the immune system’s killer T cells. Durvalumab blocks PD-L1 interaction with PD-1 and CD80, countering the tumor’s immune-evading tactics and inducing an immune response.

There is emerging evidence that combining checkpoint blockade with virotherapy could have a therapeutic effect against cancers. Viral infection of cancer cells is hypothesized to draw activated killer T cells into tumors. Once in the tumor, the T cells are exposed to telltale antigens released by dying cancer cells, potentially awakening an immune response against the malignancy as well.

Preclinical research done on mice by Zamarin and others has shown that infecting a tumor with an oncolytic virus and following up with a checkpoint blockade therapy elicits a systemic immune response that targets not only the infected tumor but also other tumors in the body. It is hoped that the GM-CSF expressed by the virus as it multiplies in cancer cells will further boost this kind of anti-tumor response.

The current trial is enrolling patients whose colorectal or ovarian cancers have become resistant to all conventional treatment and whose tumors have spread into the peritoneum–the membrane around the abdominal cavity. ONCOS-102 is being delivered directly into the peritoneal membrane, while durvalumab will be given systemically.

The objectives of this open label trial are to test the safety and preliminary efficacy of the combination, optimize dosing, evaluate the feasibility of peritoneal delivery of ONCOS-102 and inform current and future translational research.

Source:

https://www.ludwigcancerresearch.org/news/ludwig-cancer-research-and-cancer-research-institute-launch-clinical-trial-combining

Tagged with:

About author

Related Articles